Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma
- PMID: 33620716
- DOI: 10.1007/s40618-021-01514-7
Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma
Abstract
Purpose: Increasing evidence indicates that there is a correlation between papillary thyroid carcinoma (PTC) prognosis and the immune signature. Our goal was to construct a new prognostic tool based on immune genes to achieve more accurate prognosis predictions and earlier diagnoses of PTC.
Methods: The 493 PTCs samples and 58 tumor-adjacent normal tissues were obtained from The Cancer Genome Atlas database (TCGA). Immune genes were obtained from the ImmPort database. First, this cohort was randomly divided into training cohort and testing cohort. Second, the differentially expressed (DE) immune genes from the training set were used to construct the prognostic model. Then, the testing and entire data cohorts were used to validate the model, and the data were analyzed to determine the correlation of the clinical prognostic model with immune cell infiltration and expression profiles of human leukocyte antigen (HLA) genes. Finally, an analysis of the gene ontology (GO) annotation was performed.
Results: A total of 189 upregulated and 128 downregulated DE immune genes were identified. We developed and validated a three-immune gene model for PTC that includes Hsp70, NOX5, and FGF23. This model was demonstrated to be an independent prognostic variable. In addition, the overall immune activity of the high-risk group was higher than that of the low-risk group.
Conclusions: We developed and validated a three-immune gene model for PTC that includes HSPA1A, NOX5, and FGF23. This model can be used as a validated tool to predict outcomes in PTC.
Keywords: Immune gene; Papillary thyroid carcinoma; Prognosis; Risk model; TCGA.
© 2021. Italian Society of Endocrinology (SIE).
Similar articles
-
Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.Front Endocrinol (Lausanne). 2021 Jun 23;12:674616. doi: 10.3389/fendo.2021.674616. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34248843 Free PMC article.
-
Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.Virchows Arch. 2021 Nov;479(5):947-959. doi: 10.1007/s00428-021-03137-y. Epub 2021 Jun 19. Virchows Arch. 2021. PMID: 34148127
-
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.BMC Genomics. 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6. BMC Genomics. 2021. PMID: 34315405 Free PMC article.
-
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Oncotarget. 2016 Mar 15;7(11):12731-47. doi: 10.18632/oncotarget.7262. Oncotarget. 2016. PMID: 26871295 Free PMC article. Review.
-
Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications.Front Immunol. 2024 Sep 3;15:1438235. doi: 10.3389/fimmu.2024.1438235. eCollection 2024. Front Immunol. 2024. PMID: 39290709 Free PMC article. Review.
Cited by
-
Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.Onco Targets Ther. 2021 May 12;14:3119-3131. doi: 10.2147/OTT.S301127. eCollection 2021. Onco Targets Ther. 2021. PMID: 34012269 Free PMC article.
-
Analysis of the regulatory mechanisms of prognostic immune factors in thyroid cancer.Front Oncol. 2022 Dec 14;12:1059591. doi: 10.3389/fonc.2022.1059591. eCollection 2022. Front Oncol. 2022. PMID: 36591507 Free PMC article.
-
Identification of a Novel Cuproptosis-Related Gene Signature and Integrative Analyses in Thyroid Cancer.J Clin Med. 2023 Mar 3;12(5):2014. doi: 10.3390/jcm12052014. J Clin Med. 2023. PMID: 36902801 Free PMC article.
-
Non-Classical Effects of FGF23: Molecular and Clinical Features.Int J Mol Sci. 2024 Apr 30;25(9):4875. doi: 10.3390/ijms25094875. Int J Mol Sci. 2024. PMID: 38732094 Free PMC article. Review.
-
A prediction model for prognosis of gastric adenocarcinoma based on six metabolism-related genes.Biochem Biophys Rep. 2023 Feb 18;34:101440. doi: 10.1016/j.bbrep.2023.101440. eCollection 2023 Jul. Biochem Biophys Rep. 2023. PMID: 36852096 Free PMC article.
References
-
- Alzahrani AS, Xing M (2013) Impact of Iymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer 20:13–22 - DOI
-
- Omry-Orbach G (2016) Risk stratification in differentiated thyroid cancer: an ongoing process. Rambam Maimonides Med J 7(1):e0003 - DOI
-
- Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959 - DOI
-
- Zhong LK, Gan XX, Deng XY et al (2020) Potential five-mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma. Oncol Lett 20:2302–2310 - DOI
-
- Kim K, Jeon S, Kim TM, Jung CK (2018) Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers 10
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials